Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.

Tumor antigen presentation by dendritic cells (DCs) to T cells in lymphoid organs is crucial for induction of antitumor immune responses. Fms-like tyrosine kinase 3 ligand (Flt3L) is a regulator of hematopoietic cell development.
To investigate the potential effect of Flt3L transgene expression on DC-based cancer vaccines, we constructed a recombinant adenovirus AdVFlt3L expressing Flt3L, transfected DCs with AdVFlt3L, and investigated the efficacy of antitumor immunity by vaccination of DC(Flt3L) engineered to express Flt3L transgene.
Our data demonstrated that AdVFlt3L transfection up-regulated the expression of cytokine IL-1beta and chemokines MIP-1alpha, MIP-1beta, IP-10, MCP-1 and MIP-2, and stimulated DC(Flt3L) cell proliferation in vitro and migration toward regional lymph nodes in vivo. Our data also demonstrated that vaccination of Mut1-pulsed DC(Flt3L) cells was able to stimulate (i). a type 1 immune response comprising CD4(+) Th1 and CD8(+) Tc1 activation and (ii). around 2- and 3-fold enhanced tumor-specific cytotoxic T lymphocyte (CTL) and non-specific NK responses (p < 0.05) than vaccination with similarly pulsed control virus-transfected and untransfected DCs, respectively. More importantly, vaccination of Mut1-pulsed DC(Flt3L) cells induced enhanced antitumor immunity in vivo, even against poorly immunogenic 3LL tumor cells. Vaccinations of Mut1-pulsed DCs, DC(pLpA) and DC(Flt3L) all protected mice from challenge of low dose (0.5 x 10(5)) tumor cells. However, only vaccination of the last one was able to protect 63% (6/8) mice from challenge of high dose (3 x 10(5)) 3LL tumor cells (p < 0.01).
DCs engineered to secrete Flt3L may offer a new strategy in DC-based cancer vaccines.
AuthorsYongqing Liu, Hui Huang, Zhuang Chen, Li Zong, Jim Xiang
JournalThe journal of gene medicine (J Gene Med) Vol. 5 Issue 8 Pg. 668-80 (Aug 2003) ISSN: 1099-498X [Print] England
PMID12898636 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2003 John Wiley & Sons, Ltd.
Chemical References
  • Adjuvants, Immunologic
  • Cancer Vaccines
  • Chemokines
  • Cytokines
  • Membrane Proteins
  • flt3 ligand protein
  • Adenoviridae (genetics, metabolism)
  • Adjuvants, Immunologic (metabolism)
  • Animals
  • Cancer Vaccines
  • Cell Line, Tumor
  • Cell Movement (physiology)
  • Chemokines (metabolism)
  • Cytokines (metabolism)
  • Dendritic Cells (immunology, physiology)
  • Female
  • Humans
  • Immune System (physiology)
  • Killer Cells, Natural (immunology, metabolism)
  • Membrane Proteins (genetics, metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Neoplasms (immunology, metabolism)
  • Survival Rate
  • T-Lymphocytes (cytology, metabolism)
  • T-Lymphocytes, Cytotoxic (immunology, metabolism)
  • Transgenes

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: